Launch in less than 7 days!9 Dec 2025 08:09
OptiMAL® is arguably the most significant development in Fusion Antibodies’ history because it fundamentally expands what the company can offer and who it can sell to. It moves Fusion from a traditional CRO with tight margins toward a platform-driven, higher-value technology model.
1️⃣ Solving a problem competitors haven’t cracked
OptiMAL screens full-length, native human IgG antibodies in mammalian cells at scale. Most platforms still rely on phage display, which uses fragments and often needs extra engineering. OptiMAL outputs antibodies in the format pharma ultimately needs, offering the potential for better-quality hits, faster.
2️⃣ Validation from the US National Cancer Institute
Fusion reported that the NCI achieved “multiple antibody hits,” including difficult peptide targets, with “single-digit nanomolar affinities” that “exceeded our expectations.” They also stated that the NCI has asked to continue using OptiMAL for years to come. Such an endorsement from a major US research body strongly supports the platform’s capability.
3️⃣ Opening new high-margin revenue opportunities
OptiMAL could unlock platform-access fees, library screening contracts, multi-year partnerships, and potentially milestone or royalty-linked arrangements. These are longer duration and higher margin than CRO projects. Management have suggested this represents a potential “step change” for the business.
4️⃣ Positioned for the AI antibody wave
AI companies can generate billions of in-silico antibodies, but still need a mammalian system to test them. OptiMAL fills that gap, meaning Fusion could become a valuable partner for AI-driven discovery groups, biotech start-ups and pharma R&D teams.
5️⃣ Strong commercial backdrop
Fusion enters launch with positive indicators: ~£1m in pre-launch pipeline, a new commercial director hired from a mammalian display competitor, access to the £1m FMI grant, a stabilising core business, and the possibility of an NCI agreement that may involve upfront income and downstream participation. The company appears to be better prepared for a major technology rollout than at any point in recent years.
6️⃣ Potential to reshape valuation over time
Fusion has long been valued as a small CRO. OptiMAL introduces proprietary IP, external validation, higher-margin models and greater scalability. If traction builds, Fusion could start to resemble a discovery-platform company rather than a service provider. Management have noted they are “much better placed now than when our market cap was significantly higher.”
7️⃣ The culmination of years of development
OptiMAL combines Fusion’s libraries, mammalian display, engineering know-how and AI-ready workflows — effectively the platform the company has been building toward since IPO.
🔥 Summary:
OptiMAL has the potential to shift Fusion into an IP-rich, scalable, globally relevant platform validated by a major US insti
Sign In
Follow the stocks
